183 related articles for article (PubMed ID: 38329517)
1. [Liver transplantation for treatment of nonresectable primary and secondary liver malignancies : Hepatocellular and cholangiocellular carcinomas and colorectal liver metastases].
Guba M; Werner J
Chirurgie (Heidelb); 2024 Apr; 95(4):268-273. PubMed ID: 38329517
[TBL] [Abstract][Full Text] [Related]
2. [Individualized curative treatment for malignant diseases through liver transplantation].
Schwenk L; Rauchfuß F; Ali-Deeb A; Dondorf F; Rohland O; Ardelt M; Settmacher U
Chirurgie (Heidelb); 2024 Feb; 95(2):122-128. PubMed ID: 37847311
[TBL] [Abstract][Full Text] [Related]
3. Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases.
Dueland S; Syversveen T; Solheim JM; Solberg S; Grut H; Bjørnbeth BA; Hagness M; Line PD
Ann Surg; 2020 Feb; 271(2):212-218. PubMed ID: 31188200
[TBL] [Abstract][Full Text] [Related]
4. [Resection and transplantation for hepatocellular carcinoma and intrahepatic cholangiocarcinoma].
Seehofer D; Sucher R; Denecke T
Radiologe; 2022 Mar; 62(3):210-218. PubMed ID: 35080635
[TBL] [Abstract][Full Text] [Related]
5. Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun.
Hibi T; Itano O; Shinoda M; Kitagawa Y
Surg Today; 2017 Apr; 47(4):403-415. PubMed ID: 27130463
[TBL] [Abstract][Full Text] [Related]
6. Combined hepatocellular-cholangiocarcinoma with stem cell features, ductal plate malformation subtype: a case report and proposal of a new subtype.
Terada T
Int J Clin Exp Pathol; 2013; 6(4):737-48. PubMed ID: 23573322
[TBL] [Abstract][Full Text] [Related]
7. Transplantation for hepatocellular carcinoma and cholangiocarcinoma.
Campos BD; Botha JF
J Natl Compr Canc Netw; 2009 Apr; 7(4):409-16; quiz 417. PubMed ID: 19406041
[TBL] [Abstract][Full Text] [Related]
8. Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma.
Huang XW; Huang Y; Chen LD; Wang Z; Yang Z; Liu JY; Xie XY; Lu MD; Shen SL; Wang W
J Med Ultrason (2001); 2018 Apr; 45(2):231-241. PubMed ID: 29052791
[TBL] [Abstract][Full Text] [Related]
9. Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma.
Tang D; Nagano H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Dono K; Monden M
J Gastrointest Surg; 2006; 10(7):987-98. PubMed ID: 16843869
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Liver Transplantation for Hepatocellular Carcinoma Beyond the University of California San Francisco Criteria: A Single-center Experience.
Victor DW; Monsour HP; Boktour M; Lunsford K; Balogh J; Graviss EA; Nguyen DT; McFadden R; Divatia MK; Heyne K; Ankoma-Sey V; Egwim C; Galati J; Duchini A; Saharia A; Mobley C; Gaber AO; Ghobrial RM
Transplantation; 2020 Jan; 104(1):113-121. PubMed ID: 31233480
[TBL] [Abstract][Full Text] [Related]
11. New Insights in the Setting of Transplant Oncology.
Quaresima S; Melandro F; Giovanardi F; Shah K; De Peppo V; Mennini G; Ghinolfi D; Limkemann A; Pawlik TM; Lai Q
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984569
[No Abstract] [Full Text] [Related]
12. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy.
Firl DJ; Kimura S; McVey J; Hashimoto K; Yeh H; Miller CM; Markmann JF; Sasaki K; Aucejo FN
Hepatology; 2018 Oct; 68(4):1448-1458. PubMed ID: 29604231
[TBL] [Abstract][Full Text] [Related]
13. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
Agopian VG; Morshedi MM; McWilliams J; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Hiatt JR; Busuttil RW
Ann Surg; 2015 Sep; 262(3):536-45; discussion 543-5. PubMed ID: 26258323
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma.
Okuda H; Shiratori K; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2006 May; 21(5):869-73. PubMed ID: 16704538
[TBL] [Abstract][Full Text] [Related]
15. An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19.
Tsuji M; Kashihara T; Terada N; Mori H
Pathol Int; 1999 Apr; 49(4):310-7. PubMed ID: 10365850
[TBL] [Abstract][Full Text] [Related]
16. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
Tao LY; Cai L; He XD; Liu W; Qu Q
Am Surg; 2010 Nov; 76(11):1210-3. PubMed ID: 21140686
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological Features and Post-resection Prognosis of Double Primary Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Jung DH; Hwang S; Kim KH; Hong SM; Lee YJ; Ahn CS; Moon DB; Ha TY; Song GW; Park GC; Yu ES; Lee SG
World J Surg; 2017 Mar; 41(3):825-834. PubMed ID: 27812807
[TBL] [Abstract][Full Text] [Related]
18. Liver transplantation for hepatic tumors: a systematic review.
Ravaioli M; Ercolani G; Neri F; Cescon M; Stacchini G; Del Gaudio M; Cucchetti A; Pinna AD
World J Gastroenterol; 2014 May; 20(18):5345-52. PubMed ID: 24833864
[TBL] [Abstract][Full Text] [Related]
19. Response to Loco-Regional Therapy Predicts Outcomes After Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma.
Antwi SO; Habboush YY; Chase LA; Lee DD; Patel T
Ann Hepatol; 2018 Oct; 17(6):969-979. PubMed ID: 30600299
[TBL] [Abstract][Full Text] [Related]
20. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
